Group One Trading
CBIO

Group One Trading’s Crescent Biopharma CBIO Stock Holding History

Group One Trading’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-138
Closed -$3.44K – 7872
2024
Q4 		$3.44K Buy
138
+119
+626% +$3.24K ﹤0.01% 6576
2024
Q3 		$321 Sell
19
-2,145
-99% -$45K ﹤0.01% 6423
2024
Q2 		$60.9K Buy
2,164
+1,423
+192% +$148K ﹤0.01% 4377
2024
Q1 		$222K Buy
741
+18
+2% +$5.38K ﹤0.01% 3480
2023
Q4 		$171K Buy
723
+653
+933% +$102K ﹤0.01% 4001
2023
Q3 		$10.5K Sell
70
-44
-39% -$6.94K ﹤0.01% 6313
2023
Q2 		$19.8K Buy
114
+2
+2% +$335 ﹤0.01% 6001
2023
Q1 		$14.1K Buy
112
+89
+387% +$20K ﹤0.01% 5748
2022
Q4 		$6.97K Sell
23
-91
-80% -$13.4K ﹤0.01% 6188
2022
Q3 		$6K Buy
+114
New +$8.19K ﹤0.01% 6744
2022
Q1 		– Sell
-854
Closed -$123K – 8255
2021
Q4 		$123K Sell
854
-672
-44% -$122K ﹤0.01% 5540
2021
Q3 		$334K Buy
1,526
+1,302
+581% +$276K ﹤0.01% 4634
2021
Q2 		$52K Buy
+224
New +$57K ﹤0.01% 6538
2021
Q1 		– Sell
-412
Closed -$155K – 7726
2020
Q4 		$155K Buy
412
+187
+83% +$65.5K ﹤0.01% 4248
2020
Q3 		$69K Sell
225
-918
-80% -$351K ﹤0.01% 4430
2020
Q2 		$430K Buy
+1,143
New +$324K ﹤0.01% 2759
2020
Q1 		– Sell
-100
Closed -$53K – 5435
2019
Q4 		$53K Buy
100
+75
+300% +$40.6K ﹤0.01% 3979
2019
Q3 		$11K Buy
+25
New +$16.1K ﹤0.01% 4568
2018
Q3 		– Sell
-2
Closed -$3K – 5338
2018
Q2 		$3K Sell
2
-22
-92% -$37.8K ﹤0.01% 4894
2018
Q1 		$39K Buy
24
+17
+243% +$35.4K ﹤0.01% 3767
2017
Q4 		$12K Buy
+7
New +$9.26K ﹤0.01% 4321

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Group One Trading's CBIO Position: Q1 2026 in Review

Group One Trading sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 4 shares — an estimated $47 sold.

Group One Trading first reported a position in CBIO in Q4 2017 and held it in 20 quarters. The position peaked at $136K in Q3 2020. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Group One Trading reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 4 Crescent Biopharma shares in Q1 2026, an estimated $47.
  • Group One Trading first reported a position in Crescent Biopharma in Q4 2017 and held it in 20 quarters.
  • Group One Trading's Crescent Biopharma position peaked at $136K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.